Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women
- Sponsor
- Biolab Sanus Farmaceutica
- Study ID
- NCT06564883
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Menopause
- Vaginal Atrophy
- Vaginismus
Eligibility Criteria
- Sex
- FEMALE
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- 0.20% sodium hyaluronate gel — DEVICEHyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
Study Details
Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours. Hyaluronic Acid promotes vaginal moisture, providing symptom relief in various situations such as: * Vaginismus and other sexual dysfunctions related to penetration * Users of hormonal contraceptives with lubrication loss * Postpartum and lactational period * Post antibacterial or antifungal therapies * During systemic oncological treatments (chemotherapy, radiotherapy, hormone therapy) * Climacteric (urogenital atrophy) * Post urogynecological surgeries (correction of urinary incontinence, genital dystopias, etc.) * Post vulvovaginal abrasive, chemical, laser, or high-frequency therapies * Post cosmetic and genital rejuvenation therapies
Key Dates
- Start date
- Mar 1, 2025
- Status verified
- Aug 2024
- Primary completion
- Sep 30, 2025
- Completion
- Oct 30, 2025
Study Design
- Enrollment
- 45 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Experimental ArmHyaluronic Acid will applied under recommended conditions during the period of T22 ±2 days.
Primary Outcome Measure
Verify the hydration of the cutaneous and genital mucosa after using hyaluronic acid-based vaginal gel [ Time Frame: 22 days ]
Central Contacts
- Samuel Guerra Filho, MD+55 19 37898610
Related Studies
- Apple Women's Health StudyRecruiting · Apple Inc. · Boston, Massachusetts
- Autonomic Regulation of Blood Pressure in Premature and Early Menopausal WomenRecruiting · University of Minnesota · Minneapolis, Minnesota
- Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo PlaceboPHASE4 · Recruiting · Maimonides Medical Center · Brooklyn, New York
- Hot Flashes and Neurovascular Function in WomenRecruiting · Mayo Clinic · Rochester, Minnesota